AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

LQDA · NASDAQ · Medical - Pharmaceuticals

Liquidia (LQDA)

Commercializes inhaled treprostinil therapies for pulmonary hypertension and develops twice-daily L606.

$68.64

After hours0.00 (0.00%)

At close$68.64(+3.33%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	4	5	3	4	4	3	3	9	54	92	133	172
Cost of revenue	1	1	2	1	2	1	2	1	3	7	12	12
Gross profit	3	4	1	2	3	2	2	8	51	85	121	160
	18	30	30	29	32	38	37	45	49	65	59	75
Research & development	7	13	10	9	12	16	7	6	9	17	12	17
	11	17	20	20	20	21	30	39	40	48	47	57
General & administrative	11	17	20	20	20	21	30	39	40	48	0	57
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	−15	−26	−29	−27	−29	−36	−35	−38	2	20	62	86
	−1	−1	−12	−1	6	−2	−3	−4	−5	−5	−5	−4
Interest income	1	1	2	2	2	2	2	2	2	2	2	2
Interest expense	2	2	3	3	3	4	5	6	7	7	6	6
Other non-operating income	−1	−1	10	−2	−9	−2	−2	−2	−2	−2	−2	−2
Income before tax	−16	−27	−41	−28	−23	−38	−38	−42	−4	15	57	82
Income tax expense	0	0	0	0	0	0	0	0	0	0	4	7
Net income from continuing operations	−16	−27	−41	−28	−23	−38	−38	−42	−4	15	53	75
Net income	−16	−27	−41	−28	−23	−38	−38	−42	−4	15	53	75
EPS, basic	−$0.24	−$0.42	−$0.54	−$0.37	−$0.30	−$0.45	−$0.45	−$0.49	−$0.04	$0.17	$0.60	$0.84
EPS, diluted	−$0.24	−$0.42	−$0.54	−$0.37	−$0.30	−$0.45	−$0.45	−$0.49	−$0.04	$0.15	$0.52	$0.74
Weighted average shares, basic	65	66	75	76	78	85	85	86	86	87	88	89
Weighted average shares, diluted	65	66	75	76	78	85	85	86	86	100	101	101
EBITDA	−13	−25	−38	−25	−20	−33	−33	−36	4	22	64	88
Depreciation & amortization	1	0	0	1	1	1	0	0	0	0	0	0
EBIT	−14	−25	−38	−25	−20	−34	−34	−36	3	21	63	88